Ranitidine and Para drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ranitidine (ranitidine) and Para (para - aminobenzoic acid (paba)). Common drug interactions include amnesia among females and electrocardiogram qt prolonged among males.

The phase IV clinical study analyzes what interactions people have when they take Ranitidine and Para. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Ranitidine?

Ranitidine has active ingredients of ranitidine. It is often used in gastroesophageal reflux disease. eHealthMe is studying from 234,475 Ranitidine users. Check the latest studies of Ranitidine.

What is Para?

Para has active ingredients of para - aminobenzoic acid (paba). eHealthMe is studying from 2,194 Para users. Check the latest studies of Para.



On Jul, 10, 2026

15 people who take Ranitidine and Para together, and have interactions are studied.

Ranitidine and Para drug interactions.

What are the common drug interactions of Ranitidine and Para, by gender? *:

female:

  1. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  2. Blood pressure inadequately controlled
  3. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  4. Contusion (a type of hematoma of tissue in which capillaries)
  5. Depressed mood
  6. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  7. Diabetes mellitus inadequate control
  8. Diabetic retinopathy (damage to the retina caused by complications of diabetes)
  9. Drug ineffective
  10. Exercise tolerance decreased

male:

  1. Electrocardiogram qt prolonged
  2. Electrocardiogram t wave inversion

What are the common drug interactions of Ranitidine and Para, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Electrocardiogram qt prolonged
  2. Anaemia (lack of blood)
  3. Diarrhoea

30-39:

  1. Electrocardiogram qt prolonged
  2. Electrocardiogram t wave inversion

40-49:

  1. Adjustment disorder with depressed mood
  2. Anaemia (lack of blood)
  3. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  4. Diabetic retinopathy (damage to the retina caused by complications of diabetes)
  5. Diarrhoea
  6. Electrocardiogram qt prolonged
  7. Hypocalcaemia (levels of calcium in blood serum are abnormally low)
  8. Hypokalaemia (low potassium)
  9. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
  10. Refraction disorder (an error in the focusing of light by the eye)

50-59:

  1. Vomiting
  2. Anaemia (lack of blood)
  3. Cough
  4. Lipase increased
  5. Pyrexia (fever)
  6. Arthralgia (joint pain)
  7. Arthritis infective (purulent invasion of a joint by an infectious agent which produces arthritis)
  8. Decreased appetite
  9. Device failure
  10. Drug hypersensitivity

60+:

  1. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  2. Blood pressure inadequately controlled
  3. Oedema peripheral (superficial swelling)
  4. Abdominal discomfort
  5. Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
  6. Contusion (a type of hematoma of tissue in which capillaries)
  7. Depressed mood
  8. Diabetes mellitus inadequate control
  9. Drug ineffective
  10. Exercise tolerance decreased

What are the existing conditions these people have? *

  1. Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 10 people, 66.67%
  2. Anaemia (lack of blood): 5 people, 33.33%
  3. Diabetes: 4 people, 26.67%
  4. High Blood Pressure: 4 people, 26.67%
  5. Pain: 3 people, 20.00%
  6. Hiv Infection: 3 people, 20.00%
  7. Gastritis (inflammation of stomach): 3 people, 20.00%
  8. Indigestion: 3 people, 20.00%
  9. Rickets (softening of bones): 3 people, 20.00%
  10. Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood): 2 people, 13.33%

* Approximation only. Some reports may have incomplete information.

Do you take Ranitidine and Para?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Ranitidine and Para:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ranitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Para:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ranitidine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Para and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ranitidine and para - aminobenzoic acid (paba) (the active ingredients of Ranitidine and Para, respectively), and Ranitidine and Para (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: